HIND

SEC source: 0001213900-26-097218 · ownership.xml · derivative · entry 1

Jolly Mohanjit · CIK 0001867575 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,833

Underlying: Common Stock · 120,000 shares

Expires 2036-09-01

F1 · security: On September 1, 2026 the reporting person was granted an option to purchase 120,000 shares of the Issuer's common stock pursuant to the Issuer's 2025 Equity Incentive Plan. The shares subject to the option are fully vested.

F1 · kind: On September 1, 2026 the reporting person was granted an option to purchase 120,000 shares of the Issuer's common stock pursuant to the Issuer's 2025 Equity Incentive Plan. The shares subject to the option are fully vested.

F1 · derivative.exercise_date: On September 1, 2026 the reporting person was granted an option to purchase 120,000 shares of the Issuer's common stock pursuant to the Issuer's 2025 Equity Incentive Plan. The shares subject to the option are fully vested.

SEC source: 0001213900-25-111711 · ownership.xml · derivative · entry 1

Tincoff John M. III · CIK 0002085876 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,833

Underlying: Common Stock · 17,833 shares

Expires 2035-07-30

F1 · security: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc.

F1 · kind: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement the reporting person was granted 17,833 options to purchase shares of the Issuer's common stock. Of these, 4,458 options were fully vested as of the grant date. The remaining 13,375 options shall vest in twelve equal monthly installments beginning on November 30, 2025, subject to the Reporting Person's continued service on each vesting date. The options were granted under the Issuer's 2025 Equity Incentive Plan.

SEC source: 0001213900-25-111683 · ownership.xml · derivative · entry 1

Sengupta Shiladitya · CIK 0001604700 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 624,432

Underlying: Common Stock · 624,432 shares

Expires 2035-07-30

F1 · security: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc.

F2 · security: Pursuant to the Merger Agreement the reporting person was granted options to purchase 624,432 shares of the Issuer's common stock, all of which were fully vested as of the grant date. The options were granted under the Issuer's 2025 Equity Incentive Plan.

F1 · kind: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc.

F2 · kind: Pursuant to the Merger Agreement the reporting person was granted options to purchase 624,432 shares of the Issuer's common stock, all of which were fully vested as of the grant date. The options were granted under the Issuer's 2025 Equity Incentive Plan.

SEC source: 0001213900-25-111681 · ownership.xml · derivative · entry 1

Nelabhotla Venkateswarlu · CIK 0002083546 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 615,149

Underlying: Common Stock · 615,149 shares

Expires 2035-07-30

F1 · security: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc.

F2 · security: Pursuant to the Merger Agreement the reporting person was granted options to purchase 615,149 shares of the Issuer's common stock, all of which were fully vested as of the grant date. The options were granted under the Issuer's 2025 Equity Incentive Plan.

F1 · kind: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc.

F2 · kind: Pursuant to the Merger Agreement the reporting person was granted options to purchase 615,149 shares of the Issuer's common stock, all of which were fully vested as of the grant date. The options were granted under the Issuer's 2025 Equity Incentive Plan.

SEC source: 0001213900-25-112623 · ownership.xml · derivative · entry 1

Pomichter Stanley D III · CIK 0002085427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,833

Underlying: Common Stock · 17,833 shares

Expires 2035-07-30

F1 · security: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc.

F2 · security: Pursuant to the Merger Agreement the reporting person was granted 17,833 options to purchase shares of the Issuer's common stock. Of these, 4,458 options were fully vested as of the grant date. The remaining 13,375 options shall vest in twelve equal monthly installments beginning on November 30, 2025, subject to the Reporting Person's continued service on each vesting date. The options were granted under the Issuer's 2025 Equity Incentive Plan.

F1 · kind: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc.

F2 · kind: Pursuant to the Merger Agreement the reporting person was granted 17,833 options to purchase shares of the Issuer's common stock. Of these, 4,458 options were fully vested as of the grant date. The remaining 13,375 options shall vest in twelve equal monthly installments beginning on November 30, 2025, subject to the Reporting Person's continued service on each vesting date. The options were granted under the Issuer's 2025 Equity Incentive Plan.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement the reporting person was granted 17,833 options to purchase shares of the Issuer's common stock. Of these, 4,458 options were fully vested as of the grant date. The remaining 13,375 options shall vest in twelve equal monthly installments beginning on November 30, 2025, subject to the Reporting Person's continued service on each vesting date. The options were granted under the Issuer's 2025 Equity Incentive Plan.

SEC source: 0001213900-25-086999 · ownership.xml · nonDerivative · entry 1

Dickey Robert IV · CIK 0001466862 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 762

F1 · kind: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 762 shares of the Issuer's common stock in exchange for 3,810,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.

F1 · price: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 762 shares of the Issuer's common stock in exchange for 3,810,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.

SEC source: 0001213900-25-090188 · ownership.xml · nonDerivative · entry 1

Nelabhotla Venkateswarlu · CIK 0002083546 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7

F1 · kind: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 7 shares of the Issuer's common stock in exchange for 35,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.

F1 · price: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 7 shares of the Issuer's common stock in exchange for 35,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.

SEC source: 0001213900-25-112277 · ownership.xml · nonDerivative · entry 1

Jolly Mohanjit · CIK 0001867575 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 454,456

F1 · kind: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 454,456 shares of the Issuer's common stock in exchange for 2,272,280,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.

F1 · price: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 454,456 shares of the Issuer's common stock in exchange for 2,272,280,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.

F2 · ownership.nature: Includes indirect beneficial ownership of 454,456 shares of common stock held by Iron Pillar Fund I Ltd. Mohanjit Jolly is a general partner of Iron Pillar Fund I Ltd. and an advisor to and representative of Iron Pillar India Fund I for investments in the Issuer.

SEC source: 0001235802-24-000059 · primary_doc.xml · nonDerivative · entry 4

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,777

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-24-000059 · primary_doc.xml · nonDerivative · entry 3

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,825

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-24-000059 · primary_doc.xml · nonDerivative · entry 2

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,868

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-24-000059 · primary_doc.xml · nonDerivative · entry 1

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,910

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-23-000110 · primary_doc.xml · nonDerivative · entry 5

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,949

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-23-000110 · primary_doc.xml · nonDerivative · entry 4

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,080

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-23-000110 · primary_doc.xml · nonDerivative · entry 3

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,119

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-23-000110 · primary_doc.xml · nonDerivative · entry 2

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,237

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-23-000110 · primary_doc.xml · nonDerivative · entry 1

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,276

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-23-000077 · primary_doc.xml · nonDerivative · entry 1

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,384

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-23-000075 · primary_doc.xml · nonDerivative · entry 4

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,490

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.45 to $1.54, inclusive. The reporting person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001235802-23-000075 · primary_doc.xml · nonDerivative · entry 3

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,788

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-23-000075 · primary_doc.xml · nonDerivative · entry 2

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,886

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-23-000075 · primary_doc.xml · nonDerivative · entry 1

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,982

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-23-000030 · primary_doc.xml · nonDerivative · entry 4

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,091

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units (as adjusted for a reverse stock split, see footnote (2) below), all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

F2 · balance_after: On December 23, 2022, ReShape effected a 1-for-50 reverse stock split of its issued and outstanding common stock.

SEC source: 0001235802-23-000030 · primary_doc.xml · nonDerivative · entry 3

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,194

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units (as adjusted for a reverse stock split, see footnote (2) below), all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

F2 · balance_after: On December 23, 2022, ReShape effected a 1-for-50 reverse stock split of its issued and outstanding common stock.

SEC source: 0001235802-23-000030 · primary_doc.xml · nonDerivative · entry 2

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,351

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units (as adjusted for a reverse stock split, see footnote (2) below), all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

F2 · balance_after: On December 23, 2022, ReShape effected a 1-for-50 reverse stock split of its issued and outstanding common stock.

SEC source: 0001235802-23-000030 · primary_doc.xml · nonDerivative · entry 1

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,461

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units (as adjusted for a reverse stock split, see footnote (2) below), all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

F2 · balance_after: On December 23, 2022, ReShape effected a 1-for-50 reverse stock split of its issued and outstanding common stock.

SEC source: 0001235802-22-000136 · primary_doc.xml · nonDerivative · entry 4

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,404

F3 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-22-000136 · primary_doc.xml · nonDerivative · entry 3

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 327,617

F3 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-22-000136 · primary_doc.xml · nonDerivative · entry 2

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 332,761

F2 · kind: These shares were sold to cover taxes and fees in connection with the stock bonus.

SEC source: 0001235802-22-000136 · primary_doc.xml · nonDerivative · entry 1

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 697,517

F1 · shares: These shares were issued pursuant to a stock bonus granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.

SEC source: 0001235802-22-000119 · primary_doc.xml · nonDerivative · entry 2

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 332,761

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-22-000119 · primary_doc.xml · nonDerivative · entry 1

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,271

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-22-000112 · primary_doc.xml · nonDerivative · entry 2

STANKOVICH THOMAS · CIK 0001181166 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 338,670

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-22-000112 · primary_doc.xml · nonDerivative · entry 1

STANKOVICH THOMAS · CIK 0001181166 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 341,154

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-22-000109 · primary_doc.xml · nonDerivative · entry 1

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 346,963

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-22-000092 · primary_doc.xml · nonDerivative · entry 1

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 351,791

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-22-000091 · primary_doc.xml · nonDerivative · entry 1

Bandy Barton P. · CIK 0001773309 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 773,098

F1 · kind: On July 22, 2021, Mr. Bandy was awarded an aggregate of 1,186,006 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-22-000081 · primary_doc.xml · nonDerivative · entry 1

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 356,519

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-22-000080 · primary_doc.xml · nonDerivative · entry 1

Bandy Barton P. · CIK 0001773309 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 784,772

F1 · kind: On July 22, 2021, Mr. Bandy was awarded an aggregate of 1,186,006 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-22-000077 · primary_doc.xml · nonDerivative · entry 1

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 361,149

F1 · kind: On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-22-000078 · primary_doc.xml · nonDerivative · entry 2

Bandy Barton P. · CIK 0001773309 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 796,214

F1 · kind: On July 22, 2021, Mr. Bandy was awarded an aggregate of 1,186,006 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001235802-22-000078 · primary_doc.xml · nonDerivative · entry 1

Bandy Barton P. · CIK 0001773309 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 798,913

F1 · kind: On July 22, 2021, Mr. Bandy was awarded an aggregate of 1,186,006 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.

SEC source: 0001104659-22-067045 · tm2217476-1_4seq1.xml · nonDerivative · entry 8

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 365,627

SEC source: 0001104659-22-067045 · tm2217476-1_4seq1.xml · nonDerivative · entry 7

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 364,399

SEC source: 0001104659-22-067045 · tm2217476-1_4seq1.xml · nonDerivative · entry 6

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 357,860

SEC source: 0001104659-22-067045 · tm2217476-1_4seq1.xml · nonDerivative · entry 5

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 357,800

SEC source: 0001104659-22-067045 · tm2217476-1_4seq1.xml · nonDerivative · entry 4

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349,805

SEC source: 0001104659-22-067045 · tm2217476-1_4seq1.xml · nonDerivative · entry 3

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 348,805

SEC source: 0001104659-22-067045 · tm2217476-1_4seq1.xml · nonDerivative · entry 2

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 348,605

SEC source: 0001104659-22-067045 · tm2217476-1_4seq1.xml · nonDerivative · entry 1

STANKOVICH THOMAS · CIK 0001181166 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 345,705